KARPAS 707H Human myeloma cell line suitable for the generation of stable human hybridomas for the creation of fully human monoclonal antibodies.
Publications:
Karpas et al. (2001) Proc. Natl. Acad. Sci. 98, 1799–1804
Vaisbourd et al. (2001) Hybridoma & Hybridomics, 20, 287–292
Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio.
Enquiry for KARPAS 707H Human Myeloma cell line
Reagents Enquiry
To find out more about how this website collects your personal data see www.enterprise.cam.ac.uk/about-us/information-compliance/data-protection/core-privacy-notices/website-users-use-personal-information/